Skip to main content
Equibles
JAZZ logo

JAZZ · Jazz Pharmaceuticals plc · Metrics

Track JAZZ — free

Use JAZZ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JAZZ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$241.55 +1.18 (+0.49%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$15.50B
Shares
64.19M
Volume · Nov 13 496.8K Avg daily vol (3M) 874.67K

JAZZ metrics

109 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$241.55
Market cap
$15.50B

Price action

23 metrics
Price change (1W)
+2.9%
Price change (30D)
+12.7%
Price change (3M)
-1.4%
Price change (6M)
+5.6%
Price change (YTD)
+42.1%
Price change (1Y)
+70.5%
Trailing year
Price change (5Y)
+73.1%
52-week high
$261.62
52-week low
$141.07
Change from 52-week high
-7.7%
Change from 52-week low
+71.2%
Annualized volatility
38.6%
Annualized volatility (3M)
33.1%
Implied volatility (30D)
31.1%
IV rank (1Y)
31.3
IV percentile (1Y)
31.2
Beta
0.6
RSI (14D)
60.8
Price vs SMA 50
+5.4%
Price vs SMA 200
+9.8%
Avg volume (3M)
874,670
Relative volume
0.6
Average dollar volume
$205.35M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
64.19M

Valuation

12 metrics
P / E (TTM)
78.7
Trailing earnings · reciprocal yield 1.3%
PEG ratio
—
EV / revenue
4.0×
reciprocal yield 24.8%
EV / EBITDA
49.1×
reciprocal yield 2.0%
EV / EBIT
44.7×
reciprocal yield 2.2%
P / sales
3.3×
reciprocal yield 30.4%
P / book
3.7
reciprocal yield 27.0%
FCF yield
10.5%
TTM · current market cap
Buyback yield
1.5%
P / FCF
9.6
reciprocal yield 10.5%
P / operating cash flow
9.2
reciprocal yield 10.9%
Earnings yield
1.3%

Historical valuation

8 metrics
P / E historical average (3Y)
410.6×
reciprocal yield 0.2%
P / E historical average (5Y)
410.6×
reciprocal yield 0.2%
EV / revenue historical average (3Y)
3.2×
reciprocal yield 31.6%
EV / revenue historical average (5Y)
3.5×
reciprocal yield 28.4%
EV / EBIT historical average (3Y)
26.7×
reciprocal yield 3.7%
EV / EBIT historical average (5Y)
61.9×
reciprocal yield 1.6%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
33.1×
reciprocal yield 3.0%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-02

Profitability

9 metrics
Gross margin
—
Operating margin
9.0%
Trailing 12 months
Net margin
4.4%
Gross profit (TTM)
$2.20B
Operating profit (TTM)
$425.96M
Net income (TTM)
$205.95M
Trailing 12 months
Diluted EPS (TTM)
$3.07
FCF margin
34.4%
Effective tax rate
20.6%

Per share

11 metrics
Revenue per diluted share (TTM)
$72.72
Gross profit per diluted share (TTM)
$38.86
Operating profit per diluted share (TTM)
$6.51
EBITDA per diluted share (TTM)
$5.06
Net income per diluted share (TTM)
$3.12
Operating cash flow per diluted share (TTM)
$26.02
Free cash flow per diluted share (TTM)
$24.93
Capital expenditures per diluted share (TTM)
$1.09
R&D per diluted share (TTM)
$12.79
Stock compensation per diluted share (TTM)
$4.55
Book value per share
$70.30

Growth

11 metrics
Revenue growth YoY
+10.4%
Year over year
Net income growth YoY
-292.3%
Revenue (TTM)
$4.72B
Trailing 12 months
EPS growth YoY
-283.3%
Shares change YoY
+5.0%
Year over year · more shares
Revenue CAGR (3Y)
+5.3%
Revenue CAGR (5Y)
+12.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+1.4%
FCF CAGR (5Y)
+8.0%

Quality

14 metrics
Return on equity
4.9%
Return on assets
1.7%
Debt / equity
1.3
Current ratio
1.8
EBITDA (TTM)
$329.27M
Free cash flow (TTM)
$1.62B
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
2.0
Return on invested capital
4.4%
Trailing 12 months
Net cash
−$3.53B
Latest balance sheet
Cash & equivalents
$2.04B
Total assets
$12.00B
Total debt
$5.57B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.69B
Capital expenditures (TTM)
$70.75M
R&D (TTM)
$829.34M
SG&A (TTM)
$1.56B
Stock compensation (TTM)
$295.83M
R&D / revenue
17.6%
Stock compensation / revenue
6.3%

Ownership (13F)

9 metrics
13F filers
651
13F filer change QoQ
+70
Institutional ownership
100.9%
Conviction holders (share of 13F filers)
2.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-4.0%
Holder tenure
16.7
Price vs estimated holder cost
+61.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.5%

Short interest

3 metrics
Short interest
9.0%
Latest settlement · 7.7 days to cover
Days to cover
7.7d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$41.42M
Insider-sentiment score
15 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1232524 CUSIP G50871105 13F (30d) 536 filings 485 filers Visit website Investor relations